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The cardioprotective and anti-inflammatory effects of long chain omega-3
polyunsaturated fatty acids (n3 PUFA) are believed to be partly mediated by their
oxygenated metabolites (oxylipins). In the last two decades interest in a novel group
of autacoids termed specialized pro-resolving mediators (SPMs) increased. These are
actively involved in the resolution of inflammation. SPMs are multiple hydroxylated
fatty acids including resolvins, maresins, and protectins derived from the n3 PUFA
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as lipoxins
derived from arachidonic acid (ARA). In the present paper, we developed an LC-MS/MS
method for a comprehensive set of 18 SPMs derived from ARA, EPA, and DHA and
integrated it into our targeted metabolomics platform. Quantification was based on
external calibration utilizing five deuterated internal standards in combination with a
second internal standard for quality assessment of sample preparation in each sample.
The tandem mass spectrometric parameters were carefully optimized for sensitive and
specific detection. The influence of source parameters of the used AB Sciex 6500
QTRAP instrument as well as electronic parameters and the selection of transitions
are discussed. The method was validated/characterized based on the criteria listed
in the European Medicines Agency (EMA) guideline on bioanalytical method validation
and method performance is demonstrated regarding recovery of internal standards
(between 78 ± 4% and 87 ± 3% from 500 µL of human serum) as well as extraction
efficacy of SPMs in spiked plasma (intra-day accuracy within ±20 and ±15% at
0.1 and 0.3 nM in plasma, respectively). Based on the lower limit of quantification
of 0.02–0.2 nM, corresponding to 0.18–2.7 pg on column, SPMs were generally not
detectable/quantifiable in plasma and serum supporting that circulating levels of SPMs
are very low, i.e., <0.1 nM in healthy subjects. Following septic shock or peritonitis,
SPMs could be quantified in the samples of several patients. However, in these studies
with a small number of patients no clear correlation with severity of inflammation could
be observed.
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INTRODUCTION
Inflammation is a defensive mechanism of the organism to
respond to invading microorganisms or tissue injury. In an
attempt to destroy pathogens and restore normal tissue function,
inflammatory mediators, such as vasoactive amines and peptides,
cytokines, chemokines, and lipid mediators are produced
(Medzhitov, 2008). For example, lipid mediators derived from
arachidonic acid (ARA), e.g., prostaglandin E2 (PGE2) and
leukotriene B4 (LTB4) are released that act vasodilative (Higgs,
1986) and trigger the recruitment of neutrophils to the site of
inflammation (Haribabu et al., 2000). This process results in a
state of acute inflammation, which ideally leads to the elimination
of the infectious agent and is self-limited (Serhan et al., 2015). In
the past decades it was shown that the resolution of inflammation
is an active process based on the production of pro-resolving
mediators that inhibit neutrophil influx and stimulate monocytes
and macrophages in order to remove apoptotic neutrophils and
cell debris (Medzhitov, 2008; Serhan and Petasis, 2011).
Host defense and inflammation may be harmful to the
organism if it fails to resolve the inflammation and return
to homeostasis, and the resulting chronic inflammation is a
leading cause of diseases (Serhan and Petasis, 2011; Calder,
2015). Resolution of inflammation is introduced by a lipid
mediator class switching characterized by a shift from the
predominantly pro-inflammatory mediators such as leukotrienes
that amplify acute inflammation to the mostly anti-inflammatory
pro-resolving lipoxins (LX) (Levy et al., 2001). Moreover,
multiple hydroxylated fatty acids derived from the long-chain
omega-3 polyunsaturated fatty acids (n3 PUFA) eicosapentaenoic
Abbreviations: 15(R)-LXA4, 5S,6R,15R-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic acid; 17(R)-RvD1, 7S,8R, 17R-trihydroxy-4Z,9E,11E, 13Z,15E,
19Z-docosahexaenoic acid; 18(R)-RvE3, 17R, 18R- dihydroxy-5Z,8Z,11Z,13E,15E-
eicosapentaenoic acid; 18(S)-RvE3, 17R,18 S-dihydroxy-5Z,8Z,11Z,13E,
15E-eicosapentaenoic acid; 6(R)-LXA4, 5S,6R, 15S -trihydroxy-7E, 9E,11Z,13E-
eicosatetraenoic acid; 6(S)-LXA4, 5S,6S,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic acid; 7(S)-MaR1, 7S,14 S-dihydroxy-4Z,8E, 10E,12Z,16Z,19Z-
docosahexaenoic acid; ARA, arachidonic acid (20:4 n6); CAD, collision
activated dissociation; CID, collision induced dissociation; CE, collision
energy; CXP, collision cell exit potential; DHA, docosahexaenoic acid (22:6
n3); DP, declustering potential; EP, entrance potential; EPA, eicosapentaenoic
acid (20:5 n3); ESI, electrospray ionization; FIA, flow injection analysis;
HDHA, hydroxy docosahexaenoic acid; HEPE, hydroxy eicosapentaenoic
acid; HETE, hydroxy eicosatetraenoic acid; HPLC, high performance liquid
chromatography; IS, internal standard; LC, liquid chromatography; LLOQ,
lower limit of quantification; LOD, limit of detection; LX, lipoxin(s); LXA5,
5S,6R,15S-trihydroxy-7E,9E,11Z,13E,17Z-eicosapentaenoic acid; LXB4, 5S,
14R,15S-trihydroxy-6E, 8Z,10E, 12E-eicosatetraenoic acid; MaR, maresin(s);
MaR1, 7R, 14S-dihydroxy-4Z,8 E,10E,12Z,16Z,19Z-docosahexaenoic acid; MS,
mass spectrometry/ mass spectrometric; n3/n6, omega-3/omega-6; (N)PD1, 10R,
17S-dihydroxy-4Z,7Z, 11E,13E,15Z,19Z-docosahexaenoic acid; PD, peritoneal
dialysis; PDX, 10S,17S-dihydroxy-4Z,7Z,11E,13Z,15E,19Z-docosahexaenoic
acid; PUFA, polyunsaturated fatty acid; RP, reversed phase; Rv, resolvin(s);
RvD1, 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid;
RvD2, 7S, 16R,17S-trihydroxy-4Z, 8E,10Z, 12E,14E, 19Z-docosahexaenoic acid;
RvD3, 4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-docosahexaenoic acid;
RvD5, 7S, 17S-dihydroxy-4Z,8E,10Z, 13Z,15E,19Z-docosahexaenoic acid; RvE1,
5S,12R, 18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; RvE2, 5S,18R-
dihydroxy-6E,8Z,11Z,14Z,16E-eicosapentaenoic acid; S/N, signal-to-noise-ratio;
SPM, specialized pro-resolving mediator; SRM, selected reaction monitoring;
ULOQ, upper limit of quantification.
acid (EPA) and docosahexaenoic acid (DHA) including resolvins
(E- and D-series Rv), protectins and maresins (MaR) have
been described that exert inflammation resolving properties
(Figure 1) (Serhan, 2014; Bennett and Gilroy, 2016). These
classes of bioactive molecules are enzymatically formed involving
lipoxygenase (LOX), cyclooxygenase (COX) and may include
cytochrome P450 (CYP) pathways and were termed specialized
pro-resolving mediators (SPMs). As SPM production requires
several conversion steps by enzymes which are not expressed in
a single cell type, it thus requires the interplay of different cell
types during the resolution of inflammation (Serhan et al., 2014).
The anti-inflammatory activity of SPMs was demonstrated in in
vitro and in vivo models of different inflammatory diseases and
the widely appreciated health benefits associated with the intake
of long-chain n3 PUFA might partly be based on the enhanced
production of SPMs (Calder, 2015). For the formation of SPMs
the time course has to be considered, as highest levels of SPMs
are not observed during the initiation of inflammation but in the
resolution phase (Serhan and Petasis, 2011; Werz et al., 2018).
Among the firstly recognized lipid mediators involved in
the resolution of inflammation are ARA derived trihydroxy
eicosatetraenoic acids that are formed in sequential
lipoxygenations catalyzed by different LOX enzymes during cell-
cell interactions and therefore referred to as lipoxins (LX) (Serhan
et al., 1984; Serhan, 2005). Different routes of LX biosynthesis
have been described: A double lipoxygenation of ARA catalyzed
by 15-LOX and leukocyte 5-LOX leads to the formation of
an epoxy-intermediate, which is enzymatically hydrolyzed to
form both, 5(S),6(R),15(S)-trihydroxy eicosatetraenoic acid
(6(R)-LXA4) or 5(S),14(R),15(S)-trihydroxy eicosatetraenoic
acid (LXB4) (Figure 1) (Serhan, 2005). The other route of
formation involves the 5-LOX initiated synthesis of LTA4
in human neutrophils and its subsequent lipoxygenation by
platelet-type 12-LOX during neutrophil-platelet interactions
(Serhan, 2005). While LOX catalyzed LX formation leads to
15(S)-LX, 15(R)-LX are formed by aspirin acetylated COX-2
(Claria and Serhan, 1995; Serhan, 2005). Resolvins (Rv) are
formed during the resolution phase of acute inflammation
partly by cell-cell interactions from the n3 PUFA EPA and
DHA and are therefore categorized into E-series and D-series
Rv, respectively (Figure 1) (Hong et al., 2003). E-series Rv
are formed from 18(R)-hydro(pero)xy eicosapentaenoic acid
(18(R)-H(p)EPE), a hydroxylation product of EPA. The route of
formation of 18(R)-H(p)ETE is unclear and it may be catalyzed
by acetylated COX-2 in the presence of aspirin (Serhan et al.,
2000), by CYP (Arita et al., 2005) or autoxidation (Ostermann
et al., 2015). Subsequent 5-lipoxygenation of 18(R)-H(p)EPE
leads to the formation of both, 5(S),12(R),18(R)-trihydroxy
eicosapentaenoic acid (RvE1) via enzymatic hydrolysis of an
epoxy-containing intermediate or to 5(S),18(R)-dihydroxy-
eicosapentaenoic acid (RvE2) (Tjonahen et al., 2006; Serhan and
Petasis, 2011). However, also the formation of 18(S)-H(p)EPE
by acetylated COX-2 and subsequent conversion to 18(S)-RvE1
and 18(S)-RvE2 was observed (Oh et al., 2011). Another pathway
involves the action of 12/15-LOX on 18(R)- or 18(S)-H(p)EPE,
leading to the formation of pro-resolving 17(R),18(R)-dihydroxy
eicosapentaenoic acid (18(R)-RvE3) and 17(R),18(S)-dihydroxy
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FIGURE 1 | Structure and suggested formation routes of SPMs including ARA derived 4-series lipoxins, EPA derived 5-series lipoxin and E-series resolvins as well as
DHA derived maresins, D-series resolvins and protectins.
eicosapentaenoic acid (18(S)-RvE3), respectively (Isobe et al.,
2012, 2013).
D-series Rv are formed in two iterative lipoxygenation steps
(Figure 1): 17(S)-hydro(pero)xy-docosahexaenoic acid (17(S)-
H(p)DHA) is formed by 15-lipoxygenation from DHA and
serves as substrate for 5-LOX in a second lipoxygenation
step at the C-7 or C-4. Thereby, dihydroxylated RvD5 and
trihydroxylated RvD1 and RvD2 are formed (C-7) as well
as dihydroxylated RvD6 and trihydroxylated RvD3 and RvD4
(C-4) (Hong et al., 2003; Serhan and Petasis, 2011). A
second class of pro-resolving mediators derived from DHA
are dihydroxylated (neuro)protectins ((N)PD), e.g. 10(R),17(S)-
dihydroxy-docosahexaenoic acid ((N)PD1) formed from 17(S)-
H(p)DHA via an epoxide intermediate and subsequent enzymatic
hydrolysis (Hong et al., 2003; Serhan et al., 2006; Balas et al.,
2014). The 12-lipoxygenation product 14(S)-H(p)DHA serves
as precursor for a third class of DHA derived SPMs that
are synthesized by macrophages and involved in resolution of
inflammation and therefore termed maresins (MaR) (Serhan
et al., 2009). The proposed formation scheme includes—
similar to (N)PD1—a single lipoxygenation step and formation
of 7(R),14(S)-dihydroxy docosahexaenoic acid (MaR1) via an
epoxide containing intermediate (Serhan et al., 2009).
Because SPM formation involves multiple enzymatic
transformations and cell-cell interactions, concentrations of
SPMs compared to their mono-hydroxylated precursors are low
(Mas et al., 2012) and bioactivity of these potent mediators is
reported for the picomolar to lower nanomolar range (Serhan,
2017). Hence, analysis of SPMs requires powerful selective and
sensitive methodologies. Methodological approaches used for
SPM detection include gas chromatography, which was applied
e.g., for the characterization of LX (Brezinski and Serhan, 1991).
Enzyme linked immunoassays can be used for the detection
of single compounds (Chiang et al., 1998; Kirkby et al., 2013),
though their specificity might be limited with respect to a
large number of possible regio- and stereoisomers formed.
Nowadays, methods used for identification and quantification
of SPMs and other oxylipins are mostly based on reversed
phase liquid chromatography (RP-LC) (Masoodi et al., 2008;
Mas et al., 2012; Le Faouder et al., 2013; Colas et al., 2014;
Jónasdóttir et al., 2015; Skarke et al., 2015), chiral LC (Oh
et al., 2011; Homann et al., 2014; Toewe et al., 2018), or both
(Massey and Nicolaou, 2013; Barden et al., 2015) hyphenated
via electrospray ionization (ESI) to tandem mass spectrometric
(MS/MS) detection. However, despite application of state-of-the-
art LC-MS/MS based methodology, SPM detection in biological
samples remains challenging. For example, results regarding
the detection of SPMs in plasma from healthy individuals and
correlation between n3 PUFA supplementation and plasma SPM
levels are conflicting and the presence of SPMs in this matrix
has been questioned (Murphy, 2015). Whereas the biosynthesis
of SPMs in healthy individuals might be limited, increased SPM
formation is expected in inflammatory diseases or in response to
inflammatory stimuli. However, this could not be supported by
Skarke et al. and no alteration of plasma SPM levels in response
to bacterial lipopolysaccharide (LPS) during the inflammatory
or resolution phase could be observed in healthy individuals
(Skarke et al., 2015). In contrast, SPMs were detected in plasma
from patients suffering severe sepsis at levels from ∼1–500
pM (Dalli et al., 2017). Overall, it remains to be elucidated
whether SPMs circulate in blood of healthy individuals and
which endogenously formed SPMs are relevant in inflammation
(Murphy, 2015; Skarke et al., 2015).
In order to enable these studies themost sensitive and accurate
quantification in biological samples is required. Therefore, in the
present paper we developed an LC-MS/MS method using one
of the most sensitive MS instruments commercially available. A
focus was set on the optimization of instrumental parameters,
Frontiers in Pharmacology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 169
Kutzner et al. Quantification of Specialized Pro-Resolving Mediators by LC-MS
internal standard (IS) recovery, precision and accuracy for a
comprehensive set of ARA, EPA, and DHA derived SPMs.
Our LC-MS/MS method allows the simultaneous quantification
of SPMs with other enzymatically and autoxidatively formed
oxylipins. Method validation was performed oriented at the
guideline by the European Medicines Agency (EMA) on
bioanalytical method validation. Finally, the method was applied
on clinically relevant human samples from patients with and
without septic shock or peritonitis.
MATERIALS AND METHODS
Chemicals
Authentic standard substances of SPMs were purchased from
Cayman Chemicals (local distributor: Biomol, Hamburg,
Germany), i.e., resolvins (Rv) RvE1, RvD1, 17(R)-RvD1,
RvD2, RvD3, RvD5, maresins (MaR) MaR1 and 7(S)-MaR1,
protectin PDX as well as lipoxins (LX) LXA5, 6(R)-LXA4,
15(R)-LXA4, 6(S)-LXA4, and LXB4 as well as deuterated IS
including 2H5-RvD1,
2H5-RvD2,
2H5-LXA4,
2H4-LTB4, and
2H4-9,10-DiHOME. Additionally, Rv 18(R)-RvE2, 18(R)-RvE3
and 18(S)-RvE3, which were a kind gift of the lab of Makoto
Arita (RIKEN Center for Integrative Medical Sciences, Japan)
were synthesized as described (Ogawa et al., 2009; Isobe et al.,
2012, 2013). (Neuro)protectin (N)PD1 was synthesized as
follows: The (N)PD1-methyl ester was synthesized for its
C10-epimer as described (Dayaker et al., 2014) replacing the
(S)-1,2,4-butanetriol by its (R)-enantiomer as starting material
for the introduction of the E,E-iododiene. Methyl ester-(N)PD1
was than hydrolyzed with 1M LiOH in MeOH/H2O (1/1)
followed by acidification with McIlvains buffer (pH 5) producing
(N)PD1 as a colorless oil in 97% yield. Acetonitrile (ACN),
LC-MS grade methanol (MeOH) and acetic acid were obtained
from Fisher Scientific (Schwerte, Germany). HPLC grade
n-hexane and disodium hydrogen phosphate dihydrate were
purchased from Carl Roth (Karlsruhe, Germany). All other
chemicals were purchased from Sigma Aldrich (Schnelldorf,
Germany). Pure water was generated by a GenPure UF/UV
Ultrapure water system from TKA Wasseraufbereitungssysteme
GmbH (Niederelbert, Germany). For human plasma generation
human whole blood was collected into EDTA monovettes (S-
Monovette K3E, 02.1066.001, Sarstedt, Nümbrecht, Germany),
centrifuged (15min, 4◦C, 1,200 × g) and plasma was pooled
(five healthy volunteers, aged 25–38 years). For human
serum generation human whole blood was collected into
monovettes (S-Monovette with clotting activator, 02.10063,
Sarstedt, Nümbrecht, Germany), incubated for 30min at room
temperature, centrifuged (10min, 4◦C, 2,500× g) and serumwas
pooled (three healthy female subjects, aged 26–27 years). Plasma
and serum were immediately stored at−80◦C until analysis.
Mass Spectrometric Optimization
Mass spectrometric detection was performed on a 6500 QTRAP
instrument (AB Sciex, Darmstadt, Germany) coupled to a 1290
Infinity LC System (Agilent, Waldbronn, Germany). Analyses
were carried out in negative electrospray ionization (ESI(-))
mode. The influence of source parameters [electrode protrusion,
probe x- and y-axis position, source temperature, nebulizer gas
(GS1) and auxiliary (drying) gas (GS2)] was assessed in flow
injection analysis (FIA) mode injecting 5 µL of a standard
solution (100 nM) at a flow rate of 300µLmin−1 (ca. 50% Solvent
B, see below). For the Ion Drive Turbo V source (AB Sciex,
Darmstadt, Germany) the ESI probe can be arranged along the
y-axis (0 to 13mm, with 13mm representing the closest position
relative to the orifice) and optimization ranges were chosen from
0.0 to 5.0mm in steps of 0.5mm. Along the x-axis (0 to 10mm,
with 5mm as center position relative to the orifice) the ESI probe
was adjusted from 2.5 to 7.5mm in steps of 0.5mm. Additionally,
the protrusion of the electrode was adjusted with typical values
ranging from <0.5 to 2mm. The source temperature was ranged
between 300 and 550◦C (with constant GS2 60 psi), the pressure
of the auxiliary (drying) gas (GS2) was ranged from 40 to 70 psi
(with constant temperature 475◦C) and the nebulizer gas (GS1)
between 30 and 70 psi.
For MS optimization collision induced dissociation (CID)
fragment spectra were monitored (100 nM standard solution)
applying a CE range between −16 and −30V depending on
the substance. Two to three of the most intense and specific
fragments were selected and individually optimized regarding
the adjustment of electronic parameters including declustering
potential (DP), collision energy (CE), collision cell exit potential
(CXP) as well as collision activated dissociation (CAD) gas
pressure. Optimization ranges for these parameters were chosen
as follows: DP from −20 to −100V in steps of 10V, CE from
−13 to −31 (to −39 for RvD2 m/z 175.0) in steps of 2V and
re-optimized in steps of 1V, CXP from −4 to −18V in steps
of 2V. Influence of CAD gas was assessed for representative
compounds in low (6 psi), medium (9 psi) and high (15 psi) mode
for different CEs.
LC-MS/MS Method
Chromatographic separation was performed on a Zorbax Eclipse
Plus C18 reversed phase column (2.1 × 150mm, particle size
1.8µm, pore size 9.5 nm; Agilent, Waldbronn, Germany) using
a binary gradient. Solvent A was 0.1% acetic acid mixed with 5%
solvent B and solvent B was ACN/MeOH/acetic acid (800/150/1,
v/v/v). The flow rate was set to 0.3mL min−1 and the linear
gradient was as follows: 21% B at 0min, 21% B at 1.0min, 26% B
at 1.5min, 51% B at 10min, 66% B at 19min, 98% B at 25.1min,
98% B at 27.6min, 21% B at 27.7min and 21% B at 31.5min.
For MS detection the 6500 QTRAPmass spectrometer (AB Sciex,
Darmstadt, Germany) was operated in negative electrospray
ionization (ESI(-)) mode. Nitrogen was used as curtain gas and
CAD gas (nitrogen generator IMT-PN1450 PAN, INMATEC,
Herrsching, Germany). Zero air was used as nebulizer (GS1)
and drying gas (GS2) generated with an air compressor (SL-S
5.5, Renner, Güglingen, Germany) and zero air generator (UHP-
300-ZA-S-E, Parker, Kaarst, Germany). In the optimizedmethod,
the probe position was 0.250 cm along the vertical (y-) axis and
0.550 cm along the horizontal (x-) axis, electrode protrusion was
between 1 and 1.5mm, ion spray voltage was −4500V, curtain
gas (N2) was kept at 35 psi, nebulizer gas (GS1) and drying gas
(GS2) were adjusted to 60 psi each and source temperature was
475◦C. Detection was carried out in scheduled selected reaction
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monitoring (SRM) mode (detection window 90 s, cycle time
0.4 s) with the CAD gas set to 15 psi and individually optimized
electronic parameters for each SPM (Table 1). In addition to
the SPMs the method covered the quantitative detection of
175 enzymatically and chemically formed oxylipins as described
(Rund et al., 2017).
Method Characterization
Method characterization and validation was carried out in terms
of sensitivity, linearity, intraday precision and accuracy, oriented
at the guideline of the European Medicine Agency (EMA) for
bioanalytical method development (EMEA/CHMP/EWP/ Rev. 1
Corr. 2., 2011). Calibration standards covering a concentration
range from LLOQ up to 500 nM (100 nM for RvE2, 18(R)-
and 18(S)-RvE3) of SPMs were measured and linearity was
assessed by plotting the peak area ratio (analyte/IS) against the
analyte concentration (linear least square regression, weighting
1/x²). Accuracy was within ±15% of the nominal concentration
(except ±20% for LLOQ). Intraday accuracy and precision
were assessed in plasma spiked with a subset of SPMs at
four different concentration levels (0.1, 0.3, 1, and 3 nM in
plasma) and additionally in serum at one concentration level
(3 nM in serum). SPMs were spiked into plasma/serum samples
directly at the beginning of sample preparation and unspiked
plasma and serum was prepared alongside. Accuracy was
determined by comparison of the determined concentration to
the concentration in the spiking standard solution. Precision was
calculated as relative standard deviation (n= 4).
Extraction efficacy of the deuterated internal standards was
determined by calculation of the recovery rates utilizing an
internal standard 2 added at the end of sample preparation. For
evaluation of ion suppression effects by the matrix IS was spiked
into serum at the beginning of sample preparation and into the
serum extract at the end of sample preparation (post SPE).
Sample Preparation
SPMs were extracted from plasma or serum samples and eﬄuents
from peritoneal dialysis (PD) using solid phase extraction
(SPE) (Rund et al., 2017). In the first step a mixture of 20
deuterated IS (20 nM each, including 2H5-RvD1,
2H5-RvD2,
2H5-LXA4,
2H4-LTB4, and
2H4-9,10-DiHOME), antioxidant
mixture (0.2 mg/mL BHT, 100µM indomethacin, 100µM
soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-
1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) in MeOH)
were added to 500 µL of plasma/serum or 1,200 µL of
PD exudates. Then 1,400 µL ice-cold MeOH (3,360 µL for
PD exudates) were added for protein precipitation (at least
30min at−80◦C). Following centrifugation, the supernatant was
evaporated under a gentle nitrogen stream to <50% MeOH,
diluted with 0.1M disodium hydrogen phosphate buffer (pH
5.5) and loaded onto the preconditioned SPE column (Bond
Elut Certify II, 200mg, 3mL; Agilent, Waldbronn, Germany).
Oxylipins were eluted with ethyl acetate/n-hexane (75/25, v/v)
containing 1% acetic acid. After evaporation to dryness in
a vacuum concentrator (30◦C, 1 mbar, ca. 60min; Christ,
Osterode, Germany) sample extracts were reconstituted in 50 µL
MeOH containing 40 nM 1-(1-(ethylsulfonyl)piperidin-4-yl)-3-
(4-(trifluoromethoxy)phenyl)urea as IS 2. Injection volume was 5
µL; for samples with low SPM content a second (10µL) injection
was used for SPM quantification.
Clinical Samples
Peritoneal Dialysis Patient Samples
Serum and peritoneal dialysate eﬄuent samples from peritoneal
dialysis (PD) patients from the Hannover Medical School PD
outpatient clinic were obtained after written informed consent
according to the declaration of Helsinki, and local ethics board
approval (MHH 2014/6617). Patients were treated exclusively
with biocompatible PD fluids. Dialysate samples (1-2 L) with
an intra-abdominal presence ≥2 h were drained via PD catheter
from the abdomen of patients with peritonitis (n = 4–5) and
from clinically stable control patients (n = 4–5), respectively,
and immediately frozen at −80◦C until further analysis. After
coagulation in the fridge serum was centrifuged within 4 h
after sampling (10min, 2,300 × g) and frozen at −80◦C until
further analysis. In accordance with the current International
Society for Peritoneal Dialysis recommendations on prevention
and treatment of PD-related peritonitis (Li et al., 2016) a
diagnosis of peritonitis was made when at least 2 of the following
were present: (1) clinical features consistent with peritonitis,
i.e., abdominal pain and/or cloudy dialysis eﬄuent; (2) dialysis
eﬄuent white cell count >100/µL (after a dwell time of at least
2 h), with >50% polymorphonuclear; and (3) positive dialysis
eﬄuent culture.
Septic Shock Patient Samples
Plasma samples were obtained from patients with septic shock
per SEPSIS-3 definition (Singer et al., 2016) at the Hannover
Medical School ICU or healthy controls after written informed
consent according to the declaration of Helsinki and approved
by theHannoverMedical School Ethical Committee (2786-2015).
Included were 18 patients with early septic shock (<12 h) and
high need for high doses of norepinephrine (>0.4 µg/kg/min)
that were neither pregnant, aged<18 years nor had an end-stage
chronic disease. All patients were part of the recently published
EXCHANGE trial (Knaup et al., 2018). Blood was drawn within
12 h after diagnosis and plasma was centrifuged within <6 h
after sampling (10min, 3,500 × g) and frozen at −80◦C until
further analysis.
RESULTS AND DISCUSSION
In order to enable sensitive and selective detection of SPMs
electronic MS parameter were carefully optimized for each
compound and the impact of source parameters on sensitivity
was thoroughly assessed.
Optimization of Mass
Spectrometric Detection
The influence of source parameters (probe position, source gases,
source temperature) on sensitivity was assessed. Three SPMs, i.e.,
RvE1, RvD2 and RvD5 were chosen representing the structure
of di- and trihydroxy fatty acids and a broad elution window
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and thus different compositions of the mobile phase during
elution and evaporation with retention times of 6.19min (RvE1,
40% solvent B), 9.52min (RvD2, 50% solvent B) and 13.80min
(RvD5, 57% solvent B). The protrusion of the electrode was
adjusted from<0.5mm to 2mmand showed only a little effect on
the sensitivity of SPM detection (Supplementary Information).
Even though signal intensity was higher (ca. 10%) with small
protrusion, the signal was more unstable and noisier compared
to a higher protrusion. Therefore, 1–1.5mm was found to be
optimal, consistent withmanufacturer recommendation.Moving
the ESI probe closer toward the orifice along the y-axis (from 0 to
5mm), which is the closest recommended position for typical LC
flow rates of 200–1,000 µL min−1, yielded a 36% higher signal
for RvE1 (40% solvent B) and only 17% for the later eluting
RvD5 (57% solvent B). The probe position along the y-axis
was set to 2.5mm resulting in 9–20% lower signal compared to
the position at 5mm (Supplementary Information). However,
during the analysis of biological specimen a position of the probe
close to the orifice leads to a transfer of neutral compounds and
thus a rapid contamination of the MS. Unexpectedly, moving
the ESI probe farther right along the x-axis (5–7.5mm) gave
higher signal intensity of 7–10% compared to directly before
the orifice (5mm), whereas movement to the left side (5–
2.5mm) resulted in 17–27% lower signal intensity. Hence, an
off-center x-position of the ESI probe of 5.5mm was chosen
(Supplementary Information).
FIGURE 2 | Mass spectrometric optimization of electronic parameters as well as collision gas and source temperature in SRM mode for compounds RvE1, RvD2, and
RvD5. Shown is the influence of parameters on signal intensity within a range around the optimum value. (A) Source temperature (TEM) between 300 and 550◦C, (B)
declustering potential (DP) between −20 and −100V (C) collision energy (CE) in steps of 2 V from −13 to −31V for RvE1 (m/z 349→ 195) and RvD5 (m/z 359→
199), CE from −21 to −39V for RvD2 (m/z 375→ 175) with collision activated dissociation (CAD) gas set to high (15 psi), (D) collision cell exit potential (CXP) in steps
of 2 V from −4 to −18V, (E) collision energy (CE) in steps of 2 V from −13 to −31V for RvE1 (m/z 349→ 195) and RvD5 (m/z 359→ 199), CE from −21 to −39 for
RvD2 (m/z 375→ 175) with collision activated dissociation (CAD) gas set to high (15 psi), medium (9 psi) and low (6 psi).
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Overall it can be concluded that the signal intensity can
be further improved by maximal 15% (protrusion), 20% (y-
axis), and 10% (x-axis) compared to the chosen values and has
therefore only little influence on the performance of the MS for
the detection of SPMs (Supplementary Information). This can
be explained by the wide heating region and a large spray cone
compared to a relatively small orifice in the ion source. Thus, it
can be concluded that using amedium value of the recommended
ranges for the probe position seems to be sufficient as default
position for the detection of SPMs and other oxylipins.
In the next step, the influence on signal intensity of nebulizer
gas (GS1) as well as auxiliary gas (GS2) from the two heated jets
and its temperature was assessed. With optimized source gases a
signal gain of 16–23% (GS1) and 6–12% (GS2) can be achieved
(Supplementary Information) and 60 psi was selected for both
gases. The temperature was found to be a critical parameter
and was optimized in a range from 300 to 550◦C. Higher GS2
temperature led to higher intensities for RvE1 and RvD2 (36 and
45% signal gain with 550◦C compared to 300◦C). In contrast,
for later eluting RvD5 maximal intensity was observed at TEM
450◦C (Figure 2A) indicating a thermal degradation at higher
temperature. This is not only a solvent evaporation effect, because
for PGE2 (RT 8.99min) a decreasing signal intensity was also
found above 400◦C. Thus, the temperature has to be carefully
optimized, since higher temperature improves desolvatization
of stable compounds but is disadvantageous for thermo-labile
compounds, particularly those eluting with high percentage of
organic solvent leading to higher thermal stress due to faster
solvent evaporation. We selected a source temperature of 475◦C
as compromise allowing the detection of all SPMs as well as other
oxylipins. This is consistent with other methods using 400 to
580◦C for the detection of SPMs on the same instrument type
(Jónasdóttir et al., 2015; Vlasakov et al., 2016).
Careful optimization of the electronic parameters declustering
potential (DP), collision energy (CE) and collision cell exit
potential (CXP) was carried out for each individual compound
and the influence of the collision activated dissociation (CAD)
gas pressure was determined: For DP the impact on signal
intensity was minimal (<10%) within a range of −20 to −60V,
while higher DPs led to a declining signal (Figure 2B). The DP
(similar to the potential termed nozzle-skimmer voltage, cone
voltage in instruments from other companies) which is applied
to the orifice plate allows the dissociation of ion clusters. High
DP leads to in-source fragmentation due to collision with gas
molecules taking place at the relatively low vacuum in the transfer
region (Gabelica and De Pauw, 2005). Because of the large orifice
FIGURE 3 | Collision induced dissociation (CID) product ion spectra of representative SPMs comprising (A) ARA derived lipoxin 5(S),6(R),15(S)-LXA4, (B) EPA derived
E-series resolvin RvE1, (C) DHA derived D-series resolvin RvD2, (D) DHA derived protectin PDX. The dashed lines in the structures depict suggested sites of
fragmentation leading to specific transitions.
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of the instrument, which is a major difference compared to older
models of the type of instrument, only little influence on the
signal results for oxylipins within a DP between −40 and −60V.
Therefore, a standard DP of −60V could be selected for all
oxylipins, even though we used the optimal parameters for the
SPMs (Table 1).
As expected, CE led to massive differences in signal intensities
of 64–94% from highest to lowest within the tested range
(−13 to −31V; −21 to −39V for RvD2) emphasizing the
significant impact of CE on occurrence and extent of collision
induced fragmentation (CID) and thus sensitivity in SRM mode
(Figure 2C). Fine tuning was performed for each of the CEs in
steps of 1V and variation of CEs ±1V around the optimum
caused a signal decline of maximal 5% indicating that—though
a critical parameter—CE optimization in smaller steps than 2V
is not required for our instrument. For most SPMs CEs from
−19 to−23V were optimal for all fragments, in some cases such
as for RvD2 (m/z 375.3 → 175.0) higher CEs (−25 to −31V)
were required to provide sufficient energy for fragmentation in
order to ensure sensitive detection. For different adjustments
of CAD gas pressure the trend of CEs and optimal CE were
mostly similar (high, 15 psi; medium, 9 psi; low, 6 psi). CAD gas
set to “low” gave overall lowest intensities at optimal CE, while
highest intensities were observed for CAD gas set to “medium”
or “high” depending on the fragment ion (Figure 2E). This may
be caused by increasing probability for ions to undergo CID with
higher CAD gas pressure (Sleno and Volmer, 2004). On the other
hand higher potential at lower gas pressure might lead to more
intense collisions because of higher kinetic energy of the ions.
Optimal CAD gas pressure gives 16–33% higher signal intensities
compared to the lowest pressure. In our method, CAD gas is set
to high resulting in lower intensities for e.g., RvE1 (m/z 349.3→
195.0) or RvD5 (m/z 359.1 → 199.1) and better sensitivity for
RvD2 (m/z 375.3→ 175.0). Optimal collision cell exit potential
(CXP) was between −8 and −14V for all compounds and ±2V
around the optimum caused a signal decline of maximal 6%
(Figure 2D). Therefore, despite an optimal CXP was chosen, a
standard default value of −10V seems to be suitable for SPMs
and other oxylipins.
For each compound two or three specific transitions were
chosen, as exemplarily shown in Figures 3A–D, to ensure
both selective and sensitive detection and thus quantification
alongside with identification of SPMs in biological sample
material. For most of the compounds the transition with highest
sensitivity, i.e., best signal-to-noise ratio was selected as primary
transition, whereas alternative transitions were comparable (e.g.,
RvD2, PDX) or less sensitive (e.g., RvD3, 6(R)-LXA4) (Table 1).
For method characterization, quantification was carried out on
all transitions and concentrations determined with different
transitions were compared e.g., in order to evaluate matrix
interferences and support compound identity. For all compounds
α-cleavage ions referring to a cleavage of the carbon chain in
α-position of the hydroxyl group with a double bond in β-
or γ-position (α-hydroxy-β/γ-ene fragmentation mechanism)
with or without an additional loss of H2O/CO2 were used
for quantification. Their formation has been described for
SPMs and other oxylipins earlier (Murphy et al., 2005; Hong
et al., 2007; Lu et al., 2007). For example, the most sensitive
FIGURE 4 | Chromatographic separation of (A) 18 SPMs (100 nM each) and (B) 5 deuterated internal standards (20 nM) covered by the method including (C) DHA
derived D-series resolvins, (D) EPA derived E-series resolvins, (E) EPA and ARA derived lipoxins, DHA derived (F) protectins, and (G) maresins. Separation was
carried out on an RP-18 column (2.1 × 150mm, particle size 1.8µm, pore size 9.5 nm) with a H2O/MeOH/ACN/HAc gradient.
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transition selected for RvE1 (m/z 349.3 → 195.0) is based
on α-hydroxy-β-ene rearrangement, the alternative transitions
(m/z 349.3 → 205.0, m/z 349.3 → 161.0) are formed in an
α-hydroxy-γ-ene rearrangement with elimination of H2O (m/z
205.0) and of H2O/CO2 (m/z 161.0) (Figure 3B) (Lu et al.,
2007). For RvD2 the most sensitive fragment (m/z 375.3 →
175.0) is unlikely to be formed by an α-cleavage and may
be formed by a γ-cleavage toward the hydroxyl group or
another mechanism (Figure 3C). However, as this fragment
is the most sensitive with our instrument and is also used
by other groups for RvD2 (Barden et al., 2014; Homann
et al., 2014; Toewe et al., 2018), it was chosen as primary
transition. These backbone fragments [“chain-cut ions” (Hong
et al., 2007)] are specific allowing to discriminate between
regioisomers, whereas fragments referred to as “peripheral-cut
ions” (Hong et al., 2007) that result from the unspecific loss
of water (hydroxyl group) and/or carbon dioxide (carboxylic
group) are not selective and do not allow to draw conclusions
on the position of the hydroxyl groups being essential for
the selective detection of e.g., RvD5, PD1, and MaR1 (DHA-
derived dihydroxy-FA, Q1 mass: m/z 359.1) and other isobaric
autoxidation products which could be formed from PUFA.
Similar fragments were observed for the other SPMs and specific
transitions chosen are consistent with literature (Hassan and
Gronert, 2009; Mas et al., 2012; Le Faouder et al., 2013; Massey
and Nicolaou, 2013; Colas et al., 2014; Homann et al., 2014;
Jónasdóttir et al., 2015; Skarke et al., 2015; Vlasakov et al.,
2016). Overall, the selection of appropriate transitions is a crucial
step for the detection of SPMs and other oxylipins. Due to
multiple hydroxyl groups most SPMs give rise to intense ions
originating from a cleavage within the molecular backbone
allowing specific detection.
FIGURE 5 | Determination of the limit of detection (LOD) and the lower limit of
quantification (LLOQ) exemplarily shown for resolvin D2 (RvD2, m/z 375.3→
175.0). LOD is defined as peak-to-peak signal-to-noise-ratio (S/N) ≥ 3 and
LLOQ as (S/N) ≥ 5 and an accuracy within ±20% of the nominal
concentration.
Chromatographic Separation
The chromatographic separation was carried out on a state-of-
the-art C18 reversed phase column filled with sub-2µm particles
and optimized gradient. In addition to the optimized detection
described here the chromatographic separation enables the
simultaneous analysis of 175 enzymatically and autoxidatively
formed lipid mediators within 31.5min (Rund et al., 2017). The
optimized method covers a total of 18 SPMs that elute in the
first part of the chromatogram within 10min and allows the
chromatographic resolution of most of the SPMs yielding narrow
peaks with a peak width at half maximum (FWHM) of 3–4 s
(Figures 4A–G).
The chromatographic separation of SPMs is crucial due to
the large number of stereo- and regioisomers regarding position
and configuration of the hydroxyl group (R, S) bearing carbons
and the conjugated double bonds (E, Z) that exhibit identical
fragmentation patterns and similar chromatographic behavior
(Hansen et al., 2016).
Our method allows sufficient chromatographic resolution (R)
of the critical separation pairs, namely stereoisomers MaR1 and
7(S)-MaR1 (R = 4.7) and the protectins (N)PD1 and PDX
(R = 2.0) (Figures 4F,G). The two aspirin-triggered isomers
17(R)-RvD1 and 15(R)-LXA4 are not baseline separated from
17(S)-RvD1 (R = 0.9) and 6(R)-LXA4 (R = 0.6), respectively
(Figures 4C,E). With this performance the method is better or
FIGURE 6 | Recovery of deuterated internal standards (IS) used for
quantification of SPMs in 500 µL serum. Recovery of IS 1 (added directly at
the beginning of sample preparation) was determined utilizing
1-(1-(ethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea as IS 2
(added after sample preparation directly before measurement). Evaluation of
ion suppression was based on IS recovery when IS was added directly before
reconstitution of sample extract after SPE.
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comparable to that reported by other groups (Sun et al., 2007;
Mas et al., 2012), while baseline separation can be achieved
by using chiral stationary phases (Massey and Nicolaou, 2013;
Homann et al., 2014; Lehmann et al., 2015). Based on the
incomplete separation, 17(R)-RvD1 and 15(R)-LXA4 were not
included in the calibration mixture and quantification was based
on calibration curves of 17(S)-RvD1 and 6(R)-LXA4, respectively.
For RvD5 (RT 13.80min), MaR1 (RT 13.81min) and PDX (RT
13.71min) with an m/z [M-H]− of 359.1 the choice of specific
(and alternative) transitions is crucial to differentiate between
these compounds and to allow the specific quantification. The
fragmentsm/z 359.1→ 250.2 (MaR1(1)) andm/z 359.1→ 153.1
(PDX(1)) are the most intense and specific fragments for MaR1
and PDX, respectively. However, for RvD5 (m/z 359.1→ 199.1)
bothMaR1 (0.6%) and PDX (3%) show a signal on this transition.
To ensure a reliable quantification of RvD5 in presence of high
PDX concentrations a second transition (m/z 359.1 → 141.0,
RvD5(2)) was therefore included as alternative fragment.
Sensitivity
The limit of detection (LOD) and lower limit of quantification
(LLOQ) were determined according to the EMA guideline for
bioanalytical methods (EMEA/CHMP/EWP/ Rev. 1 Corr. 2.,
2011). The LOD was set to the lowest (calibration) standard
injected yielding a signal-to-noise-ratio (S/N) ≥ 3; the LLOQ
was set to the lowest calibration standard yielding an S/N ≥
5 and an accuracy within ±20% of the nominal concentration.
The S/N (peak-to-peak) was determined manually as exemplarily
shown for RvD2 (Figure 5, for LOD and LLOQ of exemplary
SPMs see Supplementary Information). As listed in Table 1,
for our method the LOD was between 0.1 and 1.5 nM (0.18–
2.7 pg on column) for the most sensitive transition, whereas
for alternative transitions similarly low or higher LODs were
determined. Despite different instrumentation, comparable or
slightly higher detection limits are reported in literature, e.g.,
3 pg on column (Mas et al., 2012), 1.3–4.9 pg on column
(Le Faouder et al., 2013), 0.10–5.2 pg on column in plasma
sample (Skarke et al., 2015) of which all used an S/N of at
least 3 as criterion. It should be noted that LODs of as low as
0.02 pg are reported for the same instrument as used in our
lab (Colas et al., 2014). However, the use of different criteria
for LOD determination might explain this huge difference of
1–2 orders of magnitude. The LLOQ ranged from 0.25 to
2.0 nM (corresponding to 0.025–0.2 nM in plasma/serum) for
the quantifier. Slightly better i.e., lower LLOQs can be achieved
with higher injection volume (10 µL: LLOQ from 0.18 to 1.0 nM
(0.018–0.1 nM in plasma/serum), Table 1). Further increasing
the injection volume resulted in an inacceptable peak shape due
to reconstitution of the sample extract in pure organic solvent
(Rund et al., 2017). Reconstitution of the sample extract in a
1:1 methanol/water mixture allows for higher injection volumes
(up to 20 µL) with acceptable peak shape for the analytes.
However, less polar oxylipins were not sufficiently dissolved
leading to unacceptable low recoveries of e.g., epoxy-FA but also
monohydroxy-FA (Supplementary Information). Therefore, it
would not be possible to accurately quantify SPM precursors
such as 17-HDHA or CYP-derived oxylipins, which may be used
as indicators for n3-PUFA supplementation (Murphy, 2015),
parallel to SPMs. Overall, it can be summarized that in our hands
under optimized conditions the lowest concentration which can
be quantified for SPMs and other oxylipins is about 1 nM in the
injected solvent corresponding to about 1 pg on column.
IS Recovery and Ion Suppression
Recovery of internal standards (IS) used for SPM quantification
was between 78 ± 4% (2H4-LTB4) and 87 ± 3% (
2H5-RvD2)
from 500 µL of human serum (n = 3, Figure 6). If the IS
was added after the solid phase extraction step recovery rates
were between 90 ± 2% (2H4-LTB4) and 105 ± 5% (
2H5-RvD2)
(Figure 6). From this it can be concluded that with the SPE
procedure as established in our laboratory (Rund et al., 2017) IS
are sufficiently well extracted from matrix (>75%) and matrix
effects are efficiently reduced (maximal ±10%). It should be
noted that IS for quantification of all other oxylipins covered
by our method show good recoveries from matrix between 72
± 3% (2H8-5-HETE) and 105 ± 6% (
2H11-5(R,S)-5-F2t-IsoP)
(Supplementary Information). Thus, it can be assumed that a
method allowing a good recovery rate of both polar oxylipins
such as prostanoids (e.g., PGE2) and less polar hydroxy-PUFA
(e.g., 5-HETE) is also appropriate for the extraction of SPMs.
Extraction Efficacy and Intraday Accuracy
and Precision
In order to evaluate the accuracy and precision of the
quantification of concentrations of SPMs in biological samples,
human plasma (with SPM levels <LOD) was spiked at four
concentration levels (0.1, 0.3, 1, and 3 nM in plasma) with a
subset of SPMs. At 0.1 nM plasma concentration and 5 µL
injection volume all of the spiked compounds were detected with
at least two different specific transitions (Table 2). Accuracies
were within ±20% of the nominal (added) concentration for the
quantifier (except RvE1) and precisions were <20%. For some
less sensitive alternative transitions 0.1 nM was below LLOQ
leading to higher variation of the determined concentrations,
as e.g., 82 ± 35% for RvD3 m/z 375.3 → 137.0 (Table 2).
However, as lower LLOQs can be achieved with higher injection
volume, better accuracies and precisions were obtained with
an injection volume of 10 µL, e.g., 103 ± 15% for RvD3 m/z
375.3 → 137.0 (Table 2). For spiking levels from 0.3 to 3 nM
in plasma determined concentrations using the quantifier were
within±15% compared to the added concentration and precision
<15%. However, also quantification using alternative transitions
resulted in acceptable accuracy (maximal ±21%) and precision
(<16%) for concentrations>LLOQ. The only exception is RvE1,
which was quantified with an accuracy of 68–81% for all spiking
levels in plasma, most likely due to interferences by the plasma
matrix, e.g., ion suppression, which was not observed in human
serum (accuracy 108% for RvE1, Table 2). Matrix interference
could also lead to the slightly higher determined concentrations
for RvD5 (121–122%) with an injection volume of 10 µL
(Table 2). In summary, all three chosen transitions were suitable
for quantification of SPMs in human plasma and serum; however,
for routine measurement the two most sensitive transitions
(one quantifier and one qualifier ion) seem to be sufficient. In
the unspiked plasma/serum of healthy individuals used for the
spiking experiment no SPMs could be detected, i.e., they did not
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exceed the LOD. It should be noted that we found good recoveries
in freshly spiked human plasma and serum samples, however, the
SPMs could be degraded during storage of the samples. Though
most oxylipins are stable during storage at −80◦C (Jonasdottir
et al., 2018) lower SPM levels have been reported in plasma which
was stored for a longer period of time (Colas et al., 2014). It would
be important to investigate the stability of naturally formed SPMs
as well as spiked analytes in future studies because this could
lead to the high concentration differences reported in biological
samples. Regarding SPM levels in human plasma and/or serum
reported concentrations differ considerably. For example, in
baseline human plasma concentrations of RvD1 and RvE1 that lie
within the working range of our method were reported, such as
0.0454 nM (RvD1) and 0.521 - 1.00 nM (RvE1) (Psychogios et al.,
2011), 0.10–0.11 nM (RvD1) and 0.11–0.14 nM (RvE1) (Barden
et al., 2014). However, also concentrations below our LLOQ were
found in human plasma, e.g., 0.007 nM RvD1 (Colas et al., 2014)
or were not detected at all (Skarke et al., 2015). In human serum
SPM amounts were considerably higher compared to the plasma
analyzed in the same study, probably due to formation during
coagulation (Colas et al., 2014). Interestingly, in another study
with plasma and serum from healthy volunteers after n3-PUFA
supplementation comparable SPM levels were found in plasma
and serum (Mas et al., 2012). Therefore, differences in sample
generation, handling and storage may impact detectability and
quantity of low levels of SPMs. In our study we could not
detect SPMs in blank plasma and serum, while in spiked samples
SPM levels as low as 0.1 nM could be detected. Thus, our study
supports earlier reports that the circulating levels of SPMs in
healthy individuals are very low, as described e.g., by Colas et al.
(2014). In order to come to comparable results regarding the
concentration of SPMs in biological samples all methods used
should be validated based on internationally accepted guidelines.
Moreover, direct comparison of results obtained by different,
independent laboratories as e.g., performed byNorris et al. (2018)
in form of round robin trials are required.
Ongoing work aims to address these questions.
SPM Formation in Peritonitis
SPMs and other oxylipins were quantified in peritoneal dialysate
and serum samples, which were obtained from patients with end
stage renal disease treated by peritoneal dialysis (PD) as renal
replacement therapy (Ellam and Wilkie, 2015) with (peritonitis,
n = 4–5) and without (control, n = 4–5) acute inflammation.
In peritoneal eﬄuents pro-inflammatory mediators PGE2 and
LTB4 were elevated in the peritonitis group compared to the
control group (Figure 7) and similar trends were observed
for the 5-, 12-, and 15-LOX products. However, SPMs were
detected only in a single sample and therefore not displayed
in Figure 7. 15-lipoxygenation products were quantified only
in low concentrations (≤1 nM) and SPM precursor 18-HEPE
was <LLOQ in >50% of the samples. In the serum 12
SPMs could be quantified in >50% of the samples including
di- and trihydroxylated ARA, EPA and DHA derived PUFA
ranging from concentrations as low as 0.24±0.074 nM (18(R)-
RvE3) to 36±15 nM (RvE2) in the peritonitis group (Figure 7,
Supplementary Information). Overall, SPM concentrations as
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well as their precursors showed no significant difference between
peritonitis and control group. A trend toward higher 5- and
12-lipoxygenation and lower 15-lipoxygenation products and
18-HEPE in peritonitis could be observed with high inter-
individual variation, while for SPMs no consistent trend toward
an elevation or reduction in peritonitis was observed (Figure 7).
For SPMs that were detected in the PD patients’ serum samples
(e.g., RvE2, RvD2) a pro-resolving action in peritonitis was
reported earlier, mainly observed as a reduction of PMN
recruitment [summarized in Serhan (2010) and Recchiuti and
Serhan (2012)]. However, these effects as well as the presence
of SPMs in peritoneal lavages were mostly shown in zymosan
induced murine peritonitis models and data on human clinical
samples are scarce. Surprisingly, no detectable levels of SPMs
were found in the dialysate of PD patients, despite being in
direct contact to the inflamed tissue within a confined space.
A reason could be the time point for sample collection, as
SPM concentrations change during the inflammation/resolution
process. In murine peritonitis models SPM formation was
reduced after the initiation of inflammation (highest after 2–
6 h, reduced/not detectable after 9–24 h) (Bannenberg et al.,
2005; Fredman et al., 2012; Divanovic et al., 2013), with
induction of a more severe, non-self-resolving inflammation
(Chiang et al., 2012; Fredman et al., 2012) or were not detected
(Dioszeghy et al., 2008; Spite et al., 2009). In clinical samples,
the individual time-course and severity of the inflammation
as well as the strong dilution of lipid mediators in the
PD solution (1–2 L) or differences in sample collection and
processing in the clinical daily routine can have an influence
on lipid mediator levels and could explain SPM levels <LLOQ
in the dialysate from peritonitis patients. The SPM pathway
markers such as 17-HDHA were elevated in the peritonitis group
FIGURE 7 | Concentration of selected lipid mediators measured in (1) peritoneal dialysate and (2) serum from patients with end stage renal disease treated with
peritoneal dialysis (PD) with (peritonitis, n = 4–5) or without (control, n = 4–5) acute inflammation. Shown are concentrations in nM as individual values and mean ±
SEM of (A) ARA derived pro-inflammatory lipid mediators, 5-, 12-, and 15-lipoxygenation products/SPM precursors as well as di- and tri-oxygenation products/SPMs
derived from (B) ARA, (C) EPA, and (D) DHA. For concentrations <LLOQ, the LLOQ is given. Mean ± SEM are only calculated if >50% of the samples are >LLOQ.
The LLOQ is indicated as dotted line. In dialysates of the control group one outlier was eliminated based on Grubb’s test (α = 0.05). Statistically significant differences
between control and peritonitis group are indicated by *p < 0.05 calculated by Mann-Whitney U test.
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compared to control group and could serve as indicator for
potential SPM formation during peritonitis. In contrast, the
overall similar levels in the serum of control and peritonitis
patients of both pro- and anti-inflammatory lipid mediators
might indicate a sustained systemic inflammation of end
stage renal disease patients. Due to the reduction in renal
clearance, poor biocompatibility of PD fluids and oxidative stress,
chronic inflammation processes are enhanced in long-term PD
patients (Lai and Leung, 2010; Velloso et al., 2014). Therefore,
elevated levels of inflammation-associated lipid mediators,
small sample size and high inter-individual variation might
mask differences in SPM concentrations between control and
peritonitis group.
SPM Formation in Septic Shock
In plasma samples from patients with septic shock [n = 18,
APACHE II score 41.5 (22–52)], severe clinical and humoral
signs of inflammation [CRP 236 mg/L (68–422 mg/L)] and
multi-organ failure, SPMs and other oxylipins were quantified
and compared to plasma samples of healthy individuals serving
as control (n = 10). In control samples, 4 SPMs (RvE2,
LXB4, (N)PD1 and PDX) were detected and exceeded LLOQ
only in 2 individuals (0.027–0.16 nM). In plasma from septic
shock patients, 12 SPMs were quantified with large inter-
individual variation ranging from <LLOQ (<0.018 nM) up to
>20 nM (Figure 8). Most SPMs including LX, E-, and D-series
Rv were quantified in less than half of the study population
(1–6 individuals), whereas protectins (N)PD1 (median conc.
0.15 nM) and PDX (median conc. 0.072 nM) were quantified
in 12–13 individuals (Figure 8). Despite high inter-individual
variation, a trend toward higher levels (median concentration)
of pro-inflammatory mediators, SPM precursors and SPMs
from different enzymatic pathways (COX, 5-LOX, 15-LOX)
and different PUFA (ARA, EPA, DHA) in plasma from septic
FIGURE 8 | Concentration of selected lipid mediators measured in plasma from patients with (sepsis, n = 18) and without (control, n = 10) septic shock. Patients with
septic shock are divided into survivors (>28 days, n = 5) and non-survivors (n = 13). Shown are concentrations in nM as individual values of (A) ARA derived PGE2,
5-lipoxygenation products and SPM pathway marker as well as SPMs derived from (B) ARA, (C) EPA, and (D) DHA. Median is given, if >50% of the samples are
>LLOQ. The LLOQ is indicated as dotted line.
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shock patients compared to control was observed. This is
consistent with earlier reports of an elevation of metabolites
formed in the ARA cascade during inflammation [e.g., in
a DSS-induced colitis model (Willenberg et al., 2015)] and
could be caused by increased phospholipase A2 (PLA2) activity
in response to the inflammatory stimuli e.g., in neutrophils
(Levy et al., 2000). A slightly more pronounced elevation
of SPM pathway markers, e.g., 17-HDHA (0.42 vs. 6.2 nM)
compared to pro-inflammatory markers such as PGE2 (0.056
vs. 0.078 nM) could suggest an attempt of the body to resolve
the inflammation; however, high mortality (72%) indicates failed
resolution. In fact, despite the small sample size higher SPMs
and their mono-hydroxylated precursors were found in non-
survivors (n = 13) compared to survivors of septic shock (n
= 5) (Figure 8). A similar observation was reported by Dalli
et al., where higher plasma concentrations of SPMs including
RvD1, RvD5, and (N)PD1 and pathway marker 17-HDHA
in sepsis non-survivors were found. It should be noted that
in this study several SPMs (e.g., PDX 0.004–0.008 nM) were
found in a concentration below our LLOQ making it difficult
to compare absolute concentrations (Dalli et al., 2017). Our
study did not unveil an obvious correlation of SPM levels to
clinical signs of inflammation, severity of sepsis or days of
survival. However, possible correlations might be masked by
the small and heterogeneous group of individuals: The patients
were of different gender, age, health condition previous septic
shock diagnosis and different pathogens were involved in the
development of septic shock. No alteration of SPMs during
inflammation or resolution phase was also observed in a human
LPS induced sepsis model (Skarke et al., 2015) or SPMs were
not detected in plasma samples from patients with hepatic
failure despite showing clinical signs of inflammation (Toewe
et al., 2018). In summary, although our study demonstrated
the presence of detectable SPM concentrations in an exemplary
cohort of extremely sick septic shock patients, it might not
support a role of SPMs as biomarkers to predict the clinical
outcome in sepsis.
CONCLUSIONS
A new method for the detection of SPMs was developed by
careful optimization of MS parameters in combination to an
UHPLC chromatographic separation using one of the most
sensitive—and commonly used for oxylipin quantification—
instruments available. The resulting LOD were 0.18–2.7 pg
on column corresponding to an LLOQ of 0.02–0.2 nM in
biological samples such as plasma. SPMs were generally
not detectable/quantifiable in plasma and serum of healthy
individuals, while good recovery rates were found in spiked
samples. These results strongly support findings that circulating
levels of SPMs are very low, i.e., <0.1 nM in healthy subjects.
In samples from patients with end stage renal disease (and
peritonitis) or septic shock SPMs and precursors were detectable;
however, not directly correlated with the health status and
clinical outcome.
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